UBS Group’s Dimension Therapeutics, Inc DMTX Stock Holding History

UBS Group’s Portfolio DMTX Stock Details DMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-113	Closed	-$1K	–	8514
2017 Q3	$1K	Sell	113 -226	-67%	-$586	﹤0.01%	7670
2017 Q2	$0	Sell	339 -59	-15%	-$80	﹤0.01%	8448
2017 Q1	$1K	Sell	398 -2,431	-86%	-$6.45K	﹤0.01%	7573
2016 Q4	$12K	Sell	2,829 -280	-9%	-$1.49K	﹤0.01%	6849
2016 Q3	$25K	Buy	3,109 +1,219	+64%	+$8.81K	﹤0.01%	6135
2016 Q2	$11K	Buy	1,890 +1,319	+231%	+$10K	﹤0.01%	6764
2016 Q1	$4K	Sell	571 -224	-28%	-$1.76K	﹤0.01%	7158
2015 Q4	$9K	Buy	+795	New	+$10.1K	﹤0.01%	7407

UBS Group's DMTX Position: Q4 2017 in Review

UBS Group sold out of Dimension Therapeutics, Inc (DMTX) in Q4 2017, closing a stake of 113 shares — an estimated $1K sold.

UBS Group first reported a position in DMTX in Q4 2015 and held it in 8 quarters. The position peaked at $25K in Q3 2016. 0 funds tracked by Wall St. Rank hold DMTX as of Q4 2017.

UBS Group reported no remaining Dimension Therapeutics, Inc position as of Q4 2017 after selling out during the quarter.
UBS Group sold 113 Dimension Therapeutics, Inc shares in Q4 2017, an estimated $1K.
UBS Group first reported a position in Dimension Therapeutics, Inc in Q4 2015 and held it in 8 quarters.
UBS Group's Dimension Therapeutics, Inc position peaked at $25K in Q3 2016.
0 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q4 2017.

Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.